2.1. Study Design
toxicity, death, pancreatic tumor
PANCREATIC TUMOR
A prospective, uncontrolled, nonrandomized, open, and multicenter study was conducted, to evaluate the safety and effectiveness of nimotuzumab, in combination with gemcitabine, in first-line treatment or recurrent patients with locally advanced and unresectable or metastatic pancreatic tumor in the real-world conditions. All included patients received a nimotuzumab fixed dose of 400 mg intravenously as a 30-minute infusion, once a week. The appearance of unacceptable toxicity were considered cause of definitive interruption, as well as the patient's refusal or death, and also, the discontinuation of nimotuzumab treatment for more than three weeks. Patients also received gemcitabine 1000 mg/m